If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 155.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 10.00 (6.667%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 155.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Board Changes

22 Apr 2022 13:01

RNS Number : 0845J
Faron Pharmaceuticals Oy
22 April 2022
 

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

 

Board Changes

 

Company announcement, April 22, 2022 at 15:01 PM (EEST) / 13:01 PM (BST) / 8:01 AM (EDT)

 

TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, is pleased to announce the appointment of Mr. Erik Ostrowski as a Non-Executive Director of the Company following the passing of the resolution regarding the election of members of the Board put to shareholders of the Company at the Annual General Meeting held earlier today. Mr. Ostrowski is an experienced biotech and financial executive who is currently the Chief Financial Officer of AVROBIO, Inc. (Nasdaq: AVRO). In addition, Matti Manner has today stepped down from his position as a Director and Vice-Chairman of the Company.

 

"We are very fortunate to welcome Erik to our Board of Directors," said Dr. Frank Armstrong, Chairman of the Board of Faron Pharmaceuticals. "He brings deep financial and biotech experience and will provide critical guidance as we continue to interact with the capital markets and increase our presence and investor base in the US. In addition to welcoming Erik, I would like to thank Matti Manner for his service to the Faron board over the past sixteen years, first as the Chairman of the Board between 2007 - 2015 and since 2015 until today as the Vice-Chairman. His partnership and contributions have been invaluable and key to the success of our Company to date."

 

Mr. Ostrowski has been AVROBIO's Chief Financial Officer and Treasurer since January 2019. AVROBIO is a clinical-stage company focused on developing gene therapies to treat rare diseases. Prior to joining AVROBIO, Mr. Ostrowski served as CFO of Summit Therapeutics plc. (Nasdaq: SMMT) and vice president of finance at Organogenesis Inc. (Nasdaq: ORGO). He previously worked in investment banking, most recently as a director with Leerink Partners LLC. Mr. Ostrowski began his career as an accountant with Coopers & Lybrand (now PricewaterhouseCoopers) and received a B.S. in accounting and economics from Babson College and a M.B.A. from the University of Chicago Booth School of Business.

 

Additional Disclosures

The following information regarding the appointment of Erik John Ostrowski, aged 49, is disclosed under Schedule 2(g) of the AIM Rules for Companies and Nasdaq First North Growth Market Rulebook.

 

Current positions, directorships and/or partnerships:

 

Former positions, directorships and/or partnerships (within the last five years):

AVROBIO Securities Corporation (a 100% owned

subsidiary of AVROBIO, Inc.)

None

 

 

Mr. Ostrowski does not have any beneficial interest in the ordinary shares or options over the ordinary shares of the Company.

 

Save as set out above, no further information regarding Mr Erik Ostrowski is required to be disclosed pursuant to the AIM Rules for Companies or Nasdaq First North Growth Market Rulebook.

 

 

 

 

For more information please contact:

 

Media / Investor Contact

Faron Pharmaceuticals

Eric Van Zanten

Head of Communications

eric.vanzanten@faron.com

investor.relations@faron.com

Phone: +1 (610) 529-6219

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

Peel Hunt LLP, Broker Christopher Golden, James SteelPhone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North Juha KarttunenPhone: +358 (0)40 555 4727Jukka JärveläPhone: +358 (0)50 553 8990

 

Consilium Strategic CommunicationsMary-Jane Elliott, David Daley, Lindsey Neville faron@consilium-comms.comPhone: +44 (0)20 3709 5700

 

 

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanized antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. Currently in Phase I/II clinical development as a potential therapy for patients with untreatable solid tumors, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of acute respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory conditions. Traumakine is currently being evaluated in global trials as a potential treatment for hospitalized patients with COVID-19 and with the 59th Medical Wing of the US Air Force and the US Department of Defense for the prevention of multiple organ dysfunction syndrome (MODS) after ischemia-reperfusion injury caused by a major trauma. Faron is headquartered in Turku, Finland with additional offices in Zürich, Switzerland and US operations in Boston, Massachusetts. Further information is available at www.faron.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAUUSARUKUSUAR
Date   Source Headline
18th Apr 20174:17 pmRNSPurchase of Shares
18th Apr 20177:00 amRNSCollaboration with Birmingham University
13th Apr 20171:43 pmRNSPurchase of Shares
4th Apr 20177:00 amRNSDirector/PDMR Shareholding
29th Mar 20177:00 amRNSFinal Results 2016
27th Mar 20179:23 amRNSHolding(s) in Company
21st Mar 201711:05 amRNSSecond Price Monitoring Extn
21st Mar 201711:00 amRNSPrice Monitoring Extension
7th Mar 201710:54 amRNSHolding(s) in Company
7th Mar 20177:00 amRNSNotice of Full Year Results
3rd Mar 201711:02 amRNSHolding(s) in Company
1st Mar 20172:05 pmRNSSecond Price Monitoring Extn
1st Mar 20172:00 pmRNSPrice Monitoring Extension
1st Mar 201711:35 amRNSResult of Placing & Subscription & Issue of Equity
28th Feb 20177:00 amRNSProposed Placing and Subscription
20th Feb 20177:00 amRNSFirst Patient Recruited in Phase II RAAA Study
9th Feb 20177:00 amRNSFaron update for 2017
9th Dec 20161:05 pmRNSNotification of Major Interest in Shares
9th Dec 20161:00 pmRNSNotification of Major Interest in Shares
5th Dec 20167:00 amRNSPDMR Shareholding
21st Nov 20167:00 amRNSGrant of options
31st Oct 20167:00 amRNSNew Application Accepted by Finnish Patent Office
24th Oct 20167:00 amRNSFirst patient recruited in Japanese Ph III trial
7th Oct 20161:41 pmRNSNotification of Major Interest in Shares
6th Oct 201610:00 amRNSNotification of Major Interest in Shares
5th Oct 20165:10 pmRNSNotification of Major Interest in Shares
26th Sep 20163:59 pmRNSDirector Dealing
21st Sep 201611:27 amRNSRaises £8.0 M through a Placing and Subscription
20th Sep 20167:00 amRNSProposed Placing & Subscription to raise £8M
5th Sep 20167:00 amRNSInterim Results for six months ended 30 June 2016
10th Aug 20167:00 amRNSFaron Pharmaceuticals Notice of Interim Results
25th Jul 20167:00 amRNSFaron enters agreement with Abzena for Clevegen
22nd Jun 201612:00 pmRNSFaron to Present at Proactive Investors Forum
14th Jun 20167:00 amRNSFaron Provides Update at R&D Day
13th Jun 20167:00 amRNSFaron Licenses Traumakine Rights to Pharmbio Korea
26th May 201610:53 amRNSFaron Result of Annual General Meeting
26th May 20167:00 amRNSFaron Expands R&D Strategy for Clevegen
13th May 20167:00 amRNSFaron Pharmaceuticals Ltd to host an R&D Day
4th May 20167:00 amRNSNotice of AGM
3rd May 20167:00 amRNSFaron Appoints New Medical Director
22nd Apr 20167:00 amRNSFaron Appoints Panmure Gordon as Joint Broker
19th Apr 20167:00 amRNSFaron Files Two New Patents to Protect Clevegen
10th Mar 20167:00 amRNSAnnual Results for the year ended 31 December 2015
1st Mar 20167:00 amRNSFaron files patent application for Traumakine
10th Feb 20167:00 amRNSNotice of Preliminary Results
7th Jan 20167:00 amRNSTop-line results from Japanese study of Traumakine
29th Dec 20157:00 amRNSFirst Patient recruited in Phase III ARDS Study
21st Dec 20157:00 amRNSFaron Awarded ?1.5 million Tekes Funding
30th Nov 20157:00 amRNSKey Publication in Journal of Immunology
17th Nov 20157:30 amRNSAdmission to AIM and first day of dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.